

1 *In vivo* detection of substantia nigra and locus coeruleus volume
2 loss in Parkinson's disease using neuromelanin-sensitive MRI:
3 Replication in two cohorts
4

5
6 Kristy S. Hwang^{1¶}, Jason Langley^{2¶}, Richa Tripathi³, Xiaoping P. Hu^{2,4}, Daniel E. Huddleston^{5*}
7

8 ¹Department of Neurosciences, University of California San Diego

9 ²Center for Advanced Neuroimaging, University of California Riverside

10 ³Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University

11 ⁴Department of Bioengineering, University of California Riverside

12 ⁵Department of Neurology, Emory University
13

14 ¶These authors contributed equally to this work
15

16 * Corresponding author:

17 E-mail: daniel.huddleston@emory.edu
18

19 **Abstract**

20 Patients with Parkinson's disease undergo a loss of melanized neurons in substantia nigra
21 pars compacta and locus coeruleus. Very few studies have assessed substantia nigra pars
22 compacta and locus coeruleus pathology in Parkinson's disease simultaneously with magnetic
23 resonance imaging (MRI). Neuromelanin-sensitive MRI measures of substantia nigra pars
24 compacta and locus coeruleus volume based on explicit magnetization transfer contrast have
25 been shown to have high scan-rescan reproducibility in controls, but no study has replicated
26 detection of Parkinson's disease-associated volume loss in substantia nigra pars compacta and
27 locus coeruleus in multiple cohorts with the same methodology.

28 Two separate cohorts of Parkinson's disease patients and controls were recruited from the
29 Emory Movement Disorders Clinic and scanned on two different MRI scanners. In cohort 1,
30 imaging data from 19 controls and 22 Parkinson's disease patients were acquired with a Siemens
31 Trio 3 Tesla scanner using a 2D gradient echo sequence with magnetization transfer preparation
32 pulse. Cohort 2 consisted of 33 controls and 39 Parkinson's disease patients who were scanned
33 on a Siemens Prisma 3 Tesla scanner with a similar imaging protocol. Locus coeruleus and
34 substantia nigra pars compacta volumes were segmented in both cohorts.

35 Substantia nigra pars compacta volume (Cohort 1: $p=0.0148$; Cohort 2: $p=0.0011$) and locus
36 coeruleus volume (Cohort 1: $p=0.0412$; Cohort 2: $p=0.0056$) were significantly reduced in the
37 Parkinson's disease group as compared to controls in both cohorts. This imaging approach
38 robustly detects Parkinson's disease effects on these structures, indicating that it is a promising
39 marker for neurodegenerative neuromelanin loss.
40

41 Introduction

42 Parkinson's disease (PD) is a heterogeneous neurodegenerative disorder with a variety of
43 motor and non-motor symptoms that can be clinically challenging to diagnose and manage, and
44 there are currently no effective interventions to stop PD neurodegeneration. Postmortem studies
45 have yielded some insights into PD biology, and by the time of symptom onset and clinical
46 diagnosis, there is an estimated 40-60% loss of pigmented dopamine neurons in the substantia
47 nigra compacta (SNc) [1-3]. Neuromelanin loss in both the SNc and the locus coeruleus (LC) are
48 hallmark pathologies in PD [3-5]. However, the role of neuromelanin in PD pathogenesis has
49 been challenging to study due to a lack of tools to investigate neuromelanin biology in living
50 patients. Studies in rodents suggest that extracellular neuromelanin triggers a neuroinflammatory
51 cascade that accelerates neurodegeneration [6, 7]. Emerging evidence from a new transgenic
52 rodent model that expresses neuromelanin in SNc indicates that neuromelanin dynamics may
53 play a key role in neurodegeneration, and neuromelanin modulating therapies for PD have been
54 proposed [8-10]. Neuroprotection trial designs could be improved with brain imaging markers of
55 neurodegeneration, including markers of change in tissue neuromelanin. These imaging markers
56 might assist participant selection and serve as surrogate outcome measures for neuroprotection
57 trials. Therefore, robust and reproducible neuroimaging measures are needed to detect and
58 quantify PD-associated neuromelanin changes *in vivo*.

59 Melanized neurons in LC and SNc can be visualized *in vivo* with neuromelanin-sensitive
60 MRI (NM-MRI) sequences using either incidental magnetization transfer effects from an
61 interleaved multi-slice turbo spin echo acquisition [11] or explicit magnetization transfer effects
62 generated by magnetization transfer preparation pulses [12-14]. Magnetization transfer contrast
63 (MTC) colocalizes with melanized neurons in LC and SNc [15, 16]. NM-MRI approaches using
64 incidental [17] or explicit [18-20] magnetization transfer effects have been found to exhibit high
65 scan-rescan reproducibility in controls, and gradient echo-based approaches with explicit
66 magnetization transfer effects exhibit the highest reproducibility [20].

67 NM-MRI can be used to assess PD-related reductions in tissue neuromelanin content in LC
68 and SNc. Application of NM-MRI approaches based on incidental magnetization transfer effects
69 to image depigmentation has revealed PD-related reductions in NM-MRI contrast ratios in SNc
70 or LC [11, 21, 22], nigral volume [23, 24], or the area of SNc in a single slice [25, 26]. Similar
71 reductions have been observed in nigral volume [12] and contrast using gradient echo NM-MRI
72 sequences that measure explicit magnetization transfer effects [27]. Nigral regions of interest,
73 derived from NM-MRI images, have also been used to examine PD-related microstructural
74 changes [28-30] or iron deposition [31, 32] in SNc.

75 Replication of imaging markers in multiple cohorts is a crucial step in the development of
76 translationally useful methods. Demonstrating reliable detection of neuromelanin loss in LC and
77 SNc would help better establish NM-MRI measures as informative to the study of PD,
78 particularly for investigation of the role of neuromelanin in its pathogenesis. Candidate markers
79 with established reproducibility would warrant further study in larger longitudinal studies, and
80 they may ultimately be applied in clinical trials for neuromelanin modulating therapies in PD and
81 related conditions. Reliable imaging of LC is particularly important for prodromal detection
82 strategies, because LC may be involved earlier in the disease course than SNc [33].

83 Reductions in nigral volume have been replicated in separate cohorts using explicit
84 magnetization transfer effect-based NM-MRI approaches [34]. However, that study did not

85 include LC volume measurement, and PD-related reductions in LC volume have not been
86 replicated separately either. This deficiency may be due to the size and stature of LC, a small
87 rod-shaped structure approximately 2 mm in diameter and 15 mm long [35]. Here we aim to
88 remedy this deficiency by applying a NM-MRI approach based on explicit magnetization
89 transfer effects to measure LC and SNc volumes in PD patients and controls in two separate
90 cohorts acquired on different MRI scanner models.

91

92 **Methods**

93

94 **Research Participants**

95 All research participants were recruited from the Emory University Movement Disorders
96 Clinic under an institutional review board approved protocol with informed written consent and
97 in accordance with the Declaration of Helsinki. Two cohorts were studied in this research, and
98 the cohorts were scanned on two different MRI scanners as described below. Cohort 1 data was
99 collected from 2012-2014 and included 19 controls and 22 PD patients. Cohort 2 consisted of 33
100 healthy controls (HC) and 39 PD patients with data collected from 2015-2016. Controls were
101 recruited from the community and the Emory Alzheimer's Disease Research Center control
102 population. PD patients fulfilled the Movement Disorders Society clinical diagnostic criteria [36],
103 and diagnosis was established by a fellowship-trained movement disorders neurologist at the
104 Emory Movement Disorders Clinic. Specific exclusion criteria included the following: 1) PD
105 patients showing symptoms or signs of secondary or atypical parkinsonism [37], 2) controls were
106 excluded if they scored ≤ 26 on the Montreal Cognitive Assessment (MOCA) indicating
107 cognitive impairment, 3) any history of vascular territorial stroke, epilepsy, multiple sclerosis,
108 neurodegenerative disease (aside from PD), peripheral neuropathy with motor deficits,
109 parenchymal brain tumor, hydrocephalus, or schizophrenia, 4) treatment with an antipsychotic
110 drug (other than quetiapine at a dose less than 200mg daily), or 5) if there were any
111 contraindications to MRI imaging.

112 PD participants had early to moderate disease with Unified Parkinson's Disease Rating Scale
113 Part III (UPDRS-III) motor score ≤ 25 in the practically defined ON state. Disease duration (in
114 years) was defined as scan date subtracted from the date of disease onset and levodopa
115 equivalent daily dose (LEDD) was also determined for PD participants. Cognition was assessed
116 using the Montreal Cognitive Assessment (MoCA) [38]. The Non-motor Symptoms
117 Questionnaire (NMSQ) [39] was used to assess non-motor symptoms. Symptoms of rapid eye
118 movement (REM) behavior disorder were assessed using the REM Sleep Behavior Disorder
119 Screening Questionnaire (RBD-SQ) [40]. Participants were evaluated on the same day as the
120 MRI scan.

121

122 **MRI Acquisition**

123 MRI data for Cohort 1 were acquired with a Siemens Trio 3 Tesla scanner (Siemens Medical
124 Solutions, Malvern, PA, USA) at Emory University with a 12-channel receive-only head coil.
125 NM-MRI data was acquired using a 2D magnetization transfer (MT) prepared gradient echo
126 (GRE) sequence [13, 14]: echo time (TE) / repetition time (TR) = 2.68 ms / 337 ms, slice

127 thickness 3 mm, in plane resolution $0.39 \times 0.39 \text{ mm}^2$, field of view (FOV) = $162 \text{ mm} \times 200 \text{ mm}$,
128 flip angle (FA) = 40° , 470 Hz/pixel bandwidth, 15 contiguous slices, and magnetization transfer
129 preparation pulse (300° , 1.2 kHz off resonance, 10 ms duration), 7 measurements, scan time 16
130 minutes 17 seconds. For registration from subject space to common space, a T_1 magnetization-
131 prepared rapid gradient echo (MP-RAGE) sequence was acquired with the following parameters:
132 TE/TR = 3.02 ms/2600 ms, inversion time = 800 ms, FA = 8° , voxel size = $1.0 \times 1.0 \times 1.0 \text{ mm}^3$.

133 Cohort 2 was scanned with a Siemens Prisma 3 Tesla scanner using a 64-channel receive-
134 only coil. NM-MRI data were acquired using a 2D GRE sequence with a MT preparation pulse:
135 TE/TR = 3.10 ms /354 ms, 15 contiguous slices, FOV = $162 \times 200 \text{ mm}^2$, in plane resolution =
136 $0.39 \times 0.39 \text{ mm}^2$, slice thickness = 3mm, 7 measurements, FA = 40° , 470 Hz/pixel receiver
137 bandwidth, and MT pulse (300° , 1.2 kHz off resonance, 10 ms duration), scan time 17 minutes
138 12 seconds. For registration, structural images were acquired with an MP-RAGE sequence:
139 TE/TR = 2.46 ms/1900 ms, inversion time = 900 ms, FA = 9° , voxel size = $0.8 \times 0.8 \times 0.8 \text{ mm}^3$.

140 On the sagittal T_1 images for both cohorts, the NM-MRI scan slices were positioned
141 perpendicular to the dorsal edge of the brainstem at midline along the fourth ventricle, starting
142 from the lower pons (below the most caudal extent of LC), with slices extending through the
143 upper midbrain to cover both SNc and LC.

144 Image Processing

145 MRI data was processed using the FMRIB Software Library (FSL). A transformation was
146 derived between each individual's T_1 -weighted image and 2 mm Montreal Neurological Institute
147 (MNI) T_1 -space using FMRIB's Linear Image Registration Tool (FLIRT) and FMRIB's
148 Nonlinear Image Registration Tool (FNIRT) in the FSL software package [41, 42]. Each
149 participant's T_1 -weighted image was brain extracted using the brain extraction tool (BET) in FSL.
150 Next, an affine transform was used to align each participant's brain extracted T_1 -weighted
151 images with the MNI brain extracted image. Finally, a nonlinear transformation was used to
152 generate a transformation from each participant's T_1 -weighted images to T_1 -weighted MNI T_1 -
153 space.

154 For each participant, individual NM-MRI measurements were corrected for motion by
155 registering the seven measurements to the first image using a rigid-body transform in FLIRT and
156 then averaged. Next, a transform was derived between each individual's T_1 -weighted image and
157 the averaged NM-MRI image with a boundary-based registration cost function.

158 SNc and LC volumes were segmented in native space using an automated thresholding
159 method. To ensure consistent placement of reference regions of interest (ROIs), a reference ROI
160 in the cerebral peduncle was created using the MNI template and the location of these reference
161 ROIs are shown in blue in Fig 1. For each subject, the cerebral peduncle ROI was transformed to
162 individual NM-MRI images using the MNI- T_1 and T_1 -NM transforms described in previous
163 paragraphs. The transform was done in a single step to reduce interpolation. The use of standard
164 space ROIs ensured that the reference ROI was placed in similar locations for each subject. The
165 mean (denoted μ_{ref}), and standard deviation (σ_{ref}) of the signal intensities were measured in the
166 reference ROI. Next, standard space SNc and LC atlases, shown in Fig 1, were used to localize
167 regions surrounding SNc and LC for thresholding [43]. These atlases were transformed from
168 standard space to individual NM-MRI images, thresholded at a level of 5%, and dilated. The
169 ROIs for thresholding were dilated to ensure that the entire SNc or LC were included for

170 thresholding. The resulting ROIs in native space are shown in red in the middle column of Fig 1.
 171 Voxels in the resulting ROIs with intensity $>\mu_{\text{ref}}+3.9\sigma_{\text{ref}}$ and $>\mu_{\text{ref}}+2.8\sigma_{\text{ref}}$ were considered to be
 172 part of LC and SNc, respectively. A higher threshold was chosen for LC to compensate for
 173 susceptibility effects from the 4th ventricle.

174 Statistical Analysis

175 All statistical analyses were performed using IBM SPSS Statistics software version 24 (IBM
 176 Corporation, Somers, NY, USA) and results are reported as mean \pm standard error. A p value of
 177 0.05 was considered significant for all statistical tests performed in this work. Normality of SNc
 178 and LC volumes was assessed using the Shapiro-Wilk test for each group and all data was found
 179 to be normal.

180 For demographic data, independent samples t-test was used to assess differences in age and
 181 years of education and Chi square was used to examine differences in **sex** and race between
 182 controls and PD in each cohort. Group means for UPDRS-III score, disease duration, levodopa
 183 equivalents, MoCA, NMSQ, and RBD-SQ were compared using a two-tailed Welch's t -test in
 184 each cohort.

185 In cohort 1, the effect of group (PD, control) was tested with separate analysis of covariance
 186 (ANCOVA) for SNc and LC volume controlling for age and education. In cohort 2, differences
 187 in SNc volume and LC volume between control and PD groups were compared using a two-
 188 tailed Welch's t -test. Pearson's correlation was used to assess the relationship between SNc
 189 volume with UPDRS-III, LEDD, MoCA and LC volume in PD for cohort 1, cohort 2, and both
 190 cohorts combined. Pearson's correlation was used to assess the relationship between LC volume
 191 and 1) UPDRS-III, and 2) MoCA for cohort 1, cohort 2, and both cohorts combined. Age was a
 192 treated as a covariate in all correlations.

193

194 Results

Group characteristics	Cohort 1			Cohort 2		
	Control	PD	P	Control	PD	P
Participants	19	22	-	33	39	-
Age	71.3 \pm 1.2	60.4 \pm 1.8	$<10^{-3}$	63.5 \pm 1.6	63.8 \pm 1.6	0.894
Sex (M:F)	9:10	13:9	0.453	11:22	22:17	0.50
Education [years]	18.2 \pm 0.5	16.3 \pm 0.5	0.015	16.7 \pm 0.4	17.0 \pm 0.6	0.661
Race [% Caucasian]	78.9%	100%	0.023	90.6%	87.2%	0.402
Disease Duration [years]	-	6.8 \pm 0.7	-	-	3.5 \pm 0.6	-
UPDRS-III	3.2 \pm 0.6	18.7 \pm 2.3	$<10^{-3}$	1.8 \pm 1.9	18.9 \pm 1.1	$<10^{-3}$
Levodopa Equivalents	-	768.8 \pm 90.4	-	-	623.3 \pm 70.8	-
MoCA	27.5 \pm 0.5	27.1 \pm 0.6	0.566	28.0 \pm 0.3	27.8 \pm 0.3	0.621
RBD-SQ	2.3 \pm 0.4	4.7 \pm 0.6	0.002	2.7 \pm 0.4	3.7 \pm 0.4	0.087
NMSQ	3.4 \pm 0.7	10.5 \pm 0.9	$<10^{-3}$	3.2 \pm 0.5	6.6 \pm 0.7	0.0006

195

196 **Table 1.** Demographic information for the groups used in this analysis. Data is presented as mean \pm
 197 standard error unless noted otherwise. Two-tailed t -tests were used for group comparisons of age,
 198 education, MoCA, RBD-SQ, and NMSQ from which p values are shown. UPDRS-III was measured in
 199 the ON state. UPDRS-III - Unified Parkinson's Disease Rating Scale Part III; MoCA - Montreal

200 Cognitive Assessment; RBD-SQ - REM Sleep Behavior Disorder Screening Questionnaire; NMSQ -
201 Non-motor Symptoms Questionnaire.
202

203 **Sample demographics**

204 In cohort 1, significant differences were in age ($p < 10^{-3}$) and education ($p = 0.015$) with
205 controls being older and having higher levels of education than the PD group. No differences
206 were seen between groups in sex ($p = 0.453$) or in MoCA score ($p = 0.556$). The PD group had
207 significantly higher UPDRS-III ($p < 10^{-3}$), RBD-SQ ($p = 0.002$), and NMSQ ($p < 10^{-3}$) scores
208 compared to the control group. In cohort 2, no difference was seen between PD and control
209 groups in age ($p = 0.894$), race ($p = 0.402$), sex ($p = 0.500$), education ($p = 0.661$), RBD-SQ score
210 ($p = 0.087$), or MoCA score ($p = 0.621$). A significant difference was seen in NMSQ ($p = 0.0006$)
211 and UPDRS-III ($p < 10^{-3}$) scores between the two groups. Demographic information is
212 summarized in **Table 1**.

213 **SNC and LC volume comparisons**

214 Figs 2 and 3 show LC and SNC in mean MTC images of both cohorts. In cohort 1, the effect
215 of group on volume was assessed with separate ANCOVAs for each ROI (SNC, LC) with age
216 and education as covariates. In SNC, results revealed a significantly smaller volume in the PD
217 group relative to the control group (Control: $474 \text{ mm}^3 \pm 31 \text{ mm}^3$; PD: $340 \text{ mm}^3 \pm 28 \text{ mm}^3$;
218 $F = 8.031$; $p = 0.007$). Similarly, a reduction in LC volume was seen in the PD group relative to the
219 control group (Control: $6.9 \text{ mm}^3 \pm 0.7 \text{ mm}^3$; PD: $4.4 \text{ mm}^3 \pm 0.7 \text{ mm}^3$; $F = 3.247$; $p = 0.049$). Age
220 was not a significant variable in the ANCOVA model for LC volume ($p = 0.238$) or SNC volume
221 ($p = 0.08$). Removal of non-Caucasian subjects did not change results, and reductions in LC
222 volume ($p = 0.048$) and SNC volume ($p = 0.005$) were seen in the PD group relative to controls. In
223 cohort 2, Welch's *t*-test was used to examine group differences in SNC volume and LC volume.
224 SNC (Control: $429 \text{ mm}^3 \pm 20 \text{ mm}^3$; PD: $329 \text{ mm}^3 \pm 17 \text{ mm}^3$; $t = 3.370$; $p = 0.0002$) and LC
225 (Control: $8.0 \text{ mm}^3 \pm 0.6 \text{ mm}^3$; PD: $5.2 \text{ mm}^3 \pm 0.6 \text{ mm}^3$; $t = 3.306$; $p = 0.0008$) volumes were
226 significantly lower in the PD group compared to the control group in cohort 2. These
227 comparisons are shown in Fig 4.

228 **Clinical Correlations**

229 In the PD group, MoCA showed a significant positive association with SNC volume in cohort
230 1 ($p = 0.012$, $r = 0.478$) and both cohorts ($p = 0.040$, $r = 0.228$) but not in cohort 2 ($p = 0.319$, $r = 0.079$).
231 SNC volume showed no significant associations with UPDRS-III or disease duration in the PD
232 group in cohort 1, cohort 2 or both cohorts ($p > 0.436$). There were no significant correlations
233 between MoCA, UPDRS-III and disease duration with LC volume in cohort 1, cohort 2, or both
234 cohorts combined for the PD group ($p > 0.272$). SNC volume showed a significant positive
235 association with LC volume in PD in both cohorts ($p = 0.012$, $r = 0.296$) but no significance in HC
236 ($p = 0.434$, $r = -0.025$). In the PD group, SNC and LC volumes had a significant positive correlation
237 in cohort 2 ($p = 0.024$, $r = 0.333$) but not in cohort 1 ($p = 0.138$, $r = 0.243$).

238 **ROC analysis**

239 In cohort 1 SNC volume outperformed LC volume as a diagnostic imaging marker of PD.
240 The area under the receiver operating characteristic (ROC) curve (AUC) for SNC volume was
241 0.756 [standard error (SE): 0.078, 95% confidence interval (CI): 0.603-0.909, $p = 0.005$] while the
242 AUC for LC volume was 0.644 [SE: 0.088, 95% CI: 0.471-0.816, $p = 0.117$]. For cohort 1,

243 combining SNc volume and LC volume yielded an AUC of 0.763 [SE: 0.074, 95% CI: 0.617-
244 0.090, $p=0.004$]. NM-MRI measures of SNc volume and LC volume performed similarly in
245 cohort 2 to differentiate PD from controls. LC volume had an AUC of 0.752 [SE: 0.063, 95% CI:
246 0.629-0.876, $p=0.001$] and SNc volume had an AUC of 0.749 [SE: 0.062, 95% CI: 0.627-0.871,
247 $p=0.001$]. For cohort 2, combining SNc volume and LC volume yielded an AUC of 0.775 [SE:
248 0.057, 95% CI: 0.664-0.886]. ROC curves for both cohorts are shown in Fig 5.

249

250 Discussion

251 This study examined PD-related loss of NM-MRI contrast in LC and SNc in two separate
252 cohorts, using two different scanner models. We observed significant volume loss in both LC
253 and SNc in the PD groups as compared to controls in both cohorts. In cohort 2, SNc volume and
254 LC volume performed similarly as diagnostic imaging markers of PD. This is the first report, to
255 our knowledge, of reproducible detection of PD-associated LC volume loss using the same NM-
256 MRI approach in multiple cohorts. It is also the first report of simultaneous imaging of LC and
257 SNc detecting PD effects in both structures in discovery and validation cohorts. The NM-MRI
258 pulse sequence and image processing methods that were used in this study have previously
259 established high scan-rescan reproducibility [18, 20]. To increase reproducibility and ensure
260 consistent placement of ROIs, reference regions and regions within which to threshold voxels for
261 volume measurement were defined using standard space ROIs and transformed to each
262 individual's NM-MRI image. These ROIs were then used to define thresholded and reference
263 regions in the SNc and LC segmentation procedure. The results of this study, therefore, support
264 the utility of these NM-MRI methods as a robust and reproducible approach to measure PD
265 neuropathology *in vivo*.

266 The two Parkinsonian cohorts used in this study had similar motor impairment, but different
267 disease durations. The mean and standard error of nigral volume was strikingly consistent across
268 both cohorts. The consistency in SNc volume loss may be due to similarity of NM-MRI
269 protocols used in this study. A previous study assessed LC volume measurements using multiple
270 types of scanners [34], but used different implementations of NM-MRI protocols to image LC.
271 The authors found differences in NM-MRI measures of LC between scanners, but it was not
272 clear whether these differences resulted from the variability in scanning protocols or the scanners
273 themselves. Here, we observed a non-significant trend toward an LC volume difference between
274 the two cohorts in the control groups ($p=0.081$). Because the NM-MRI protocols were very
275 similar, this result suggests that differences between the Prisma and Trio scanner types (the
276 former having higher signal to noise ratio due to signal digitization at the receiver coil) may
277 enable the Prisma to detect NM-MRI contrast in LC more readily than the Trio scanner. This
278 result should be interpreted cautiously though, because an alternative explanation is that the older
279 control group in cohort 1 may have had lower LC volume than cohort 2 due to aging effects.

280 The performance of cohort 1 LC volume as a diagnostic marker of PD was similar to the
281 AUC reported in a previous study, and cohort 2 LC volume outperformed that observed in the
282 prior study [34]. Improved performance of LC volume in cohort 2 may be due to several factors.
283 First, the Siemens Trio MRI scanner used in cohort 1 has a higher noise profile than the Siemens
284 Prisma MRI scanner used in cohort 2, and elevated noise likely reduced efficacy of LC volume

285 as a diagnostic marker in cohort 1. Second the control group was significantly older than the PD
286 group in cohort 1. Neuromelanin peaks in LC between age 50-60 and declines after age 60 [44-
287 46]. Thus, this age difference may have reduced the effect size by reducing the mean LC volume
288 in the control group.

289 The ROC analysis found AUC of nigral volume in both cohorts to have AUCs comparable to
290 previously published nigral diagnostic imaging markers of PD [27, 34, 47-50]. However, these
291 AUCs are below thresholds typically used for individual clinical diagnosis ($AUC > 0.9$).
292 Combining LC and nigral volume increased the AUC in both cohorts ($AUC = 0.763$ and $AUC =$
293 0.775 for cohorts 1 and 2, respectively) and these values are approaching levels that are clinically
294 useful. Diagnostic accuracy may be improved by combining nigral markers from other MRI
295 contrasts, such as those from iron [28, 31, 32, 51] or diffusion [29, 52] contrasts.

296 Nigrosome-1 is the subregion of SNc that experiences the greatest reductions in melanized
297 neurons and is found in the lateral-ventral portion of SNc [53, 54]. This region can be visualized
298 in T_2 - or T_2^* -weighted images as a relatively hyperintense region in the substantia nigra, and loss
299 of this hyperintensity in PD patients has shown promise as a diagnostic imaging marker [55]. In
300 NM-MRI images, nigrosome-1 has been localized to the lateral-ventral portion of SNc, which is
301 consistent with its localization in postmortem neuropathology studies [3, 53, 56]. We observed
302 reductions in NM-sensitive contrast in the lateral-ventral regions of SNc (see Fig 3) in both
303 cohorts. This is in agreement with earlier studies that found volume loss or reductions in
304 neuromelanin-sensitive contrast in the posterior portion of SNc [57] or in the lateral-ventral tier
305 of SNc [27]. Studies examining PD-related changes using other MRI contrasts have found
306 increases in free water [58, 59], which may be associated with neurodegeneration [60], in
307 posterior nigral ROIs as well as elevated iron levels in the lateral-ventral tier [61, 62]. Taken
308 together, these changes may manifest from neurodegeneration in nigrosome-1.

309 There are several caveats to this study. First, UPDRS-III was measured in the on-medication
310 state. Earlier studies found a significant relationship between nigral volume and UPDRS score
311 [34] and lack of correlation between nigral volume and UPDRS-III score may be due to
312 measurement in the on-medication state. This may also have been due to the inclusion of PD
313 patients with similar early to moderate disease stage, and a lack of PD patients with more severe
314 motor symptoms. Second, the control group in cohort 1 was significantly older and more
315 educated than the PD group. This may have reduced the effect size for LC volume. Finally, we
316 elected to use 3 mm slices in the acquisition to ensure sufficient signal to noise ratio (SNR) for
317 SNc and LC segmentation, which may increase partial volume effects.

318 NM-MRI approaches based on explicit magnetization transfer effects have already
319 demonstrated high scan-rescan reproducibility [18-20]. The current findings provide additional
320 evidence that NM-MRI robustly and reproducibly detects PD-related reductions in volume in
321 both LC and SNc. In the context of emerging evidence for a mechanistic role for neuromelanin
322 in PD [8-10], these findings may inform strategies to study disease pathophysiology and
323 ultimately assist therapeutics development. Therefore, investigation of these NM-MRI measures
324 as candidate biomarkers in larger, longitudinal studies is warranted. They have potential for
325 development both as individual markers and as part of multivariate profiles incorporating iron-
326 sensitive and diffusion-sensitive MRI modalities.

327
328 **Author Roles**

329 1) Research project: A. Conception, B. Organization, C. Execution; 2) Statistical Analysis: A. Design, B.
330 Execution, C. Review and Critique; 3) Manuscript: A. Writing of the first draft, B. Review and Critique.

331 K.H. 1C, 2A, 2B, 2C, 3A, 3B

332 J.L.: 1A, 1B, 1C, 2A, 2C, 2B, 3A, 3B

333 R.T.: 2B, 2C, 3B

334 X.H: 1A, 1C, 2C, 3B

335 D.H.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B

336 **Financial Disclosures**

337 Dr. Huddleston and Dr. Hu are inventors on an issued patent relating to the NM-MRI pulse sequence (US
338 Patent number 9600881) and Dr. Huddleston is an inventor on a published patent application (US-
339 2021/0007603-A1) relating to the image processing methods reported.

340 **Acknowledgements**

341 The authors would like to express their gratitude to Ms. Kelsey Tucker for assistance with data
342 acquisition.
343

344 **References**

- 345
346 1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. *Neuron*. 2003;39(6):889-909. Epub
347 2003/09/16. doi: 10.1016/s0896-6273(03)00568-3. PubMed PMID: 12971891.
- 348 2. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons.
349 *Ann Neurol*. 2010;67(6):715-25. Epub 2010/06/03. doi: 10.1002/ana.21995. PubMed PMID: 20517933; PubMed
350 Central PMCID: PMCPMC2918373.
- 351 3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain*.
352 1991;114(Pt 5):2283 - 301. PubMed PMID: doi:10.1093/brain/114.5.2283.
- 353 4. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal Loss Is Greater in the Locus Coeruleus Than
354 Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases. *Arch Neurol*. 2003;60(3):337-41. doi:
355 10.1001/archneur.60.3.337.
- 356 5. Chan-Palay V. Locus Coeruleus and Norepinephrine in Parkinson's Disease. *Psychiatry and Clinical
357 Neurosciences*. 1991;45(2):519-21. doi: 10.1111/j.1440-1819.1991.tb02540.x.
- 358 6. Viceconte N, Burguillos MA, Herrera AJ, De Pablos RM, Joseph B, Venero JL. Neuromelanin activates
359 proinflammatory microglia through a caspase-8-dependent mechanism. *J Neuroinflammation*. 2015;12:5. doi:
360 10.1186/s12974-014-0228-x. PubMed PMID: 25586882; PubMed Central PMCID: PMCPMC4302615.
- 361 7. Zecca L, Wilms H, Geick S, Claasen JH, Brandenburg LO, Holzknacht C, et al. Human neuromelanin
362 induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
363 *Acta Neuropathol*. 2008;116(1):47-55. Epub 2008/03/18. doi: 10.1007/s00401-008-0361-7. PubMed PMID:
364 18343932.
- 365 8. Carballo-Carbajal I, Laguna A, Romero-Gimenez J, Cuadros T, Bove J, Martinez-Vicente M, et al. Brain
366 tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.


- 367 Nat Commun. 2019;10(1):973. doi: 10.1038/s41467-019-08858-y. PubMed PMID: 30846695; PubMed Central
368 PMCID: PMC6405777.
- 369 9. Vila M, Laguna A, Carballo-Carbajal I. Intracellular crowding by age-dependent neuromelanin
370 accumulation disrupts neuronal proteostasis and triggers Parkinson disease pathology. *Autophagy*.
371 2019;15(11):2028-30. Epub 2019/09/05. doi: 10.1080/15548627.2019.1659621. PubMed PMID: 31480882;
372 PubMed Central PMCID: PMC6844506.
- 373 10. Vila M. Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease. *Mov Disord*.
374 2019;34(10):1440-51. Epub 2019/06/30. doi: 10.1002/mds.27776. PubMed PMID: 31251435; PubMed Central
375 PMCID: PMC67079126.
- 376 11. Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, et al. Neuromelanin magnetic
377 resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. *Neuroreport*. 2006;17(11):1215-8.
378 Epub 2006/07/14. doi: 10.1097/01.wnr.0000227984.84927.a700001756-200607310-00027 [pii]. PubMed PMID:
379 16837857.
- 380 12. Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, et al. 3D neuromelanin-sensitive magnetic
381 resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of
382 Parkinson's disease. *Neuroradiology*. 2013;55(6):719-24. Epub 2013/03/26. doi: 10.1007/s00234-013-1171-8.
383 PubMed PMID: 23525598.
- 384 13. Chen X, Huddleston DE, Langley J, Ahn S, Barnum CJ, Factor SA, et al. Simultaneous imaging of locus
385 coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. *Magn Reson Imaging*.
386 2014;32(10):1301-6. Epub 2014/08/03. doi: S0730-725X(14)00206-9 [pii]10.1016/j.mri.2014.07.003. PubMed
387 PMID: 25086330.
- 388 14. Langley J, Huddleston DE, Chen X, Sedlacik J, Zachariah N, Hu X. A multicontrast approach for
389 comprehensive imaging of substantia nigra. *Neuroimage*. 2015;112:7-13. doi: 10.1016/j.neuroimage.2015.02.045.
390 PubMed PMID: 25731994.
- 391 15. Keren NI, Taheri S, Vazey EM, Morgan PS, Granholm AC, Aston-Jones GS, et al. Histologic validation of
392 locus coeruleus MRI contrast in post-mortem tissue. *Neuroimage*. 2015;113(1):235-45. doi:
393 10.1016/j.neuroimage.2015.03.020. PubMed PMID: 25791783.
- 394 16. Kitao S, Matsusue E, Fujii S, Miyoshi F, Kaminou T, Kato S, et al. Correlation between pathology and
395 neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies. *Neuroradiology*. 2013;55(8):947-
396 53. Epub 2013/05/16. doi: 10.1007/s00234-013-1199-9. PubMed PMID: 23673875.
- 397 17. Tona KD, Keuken MC, de Rover M, Lakke E, Forstmann BU, Nieuwenhuis S, et al. In vivo visualization
398 of the locus coeruleus in humans: quantifying the test-retest reliability. *Brain Struct Funct*. 2017. doi:
399 10.1007/s00429-017-1464-5. PubMed PMID: 28647901.
- 400 18. Langley J, Huddleston DE, Liu CJ, Hu X. Reproducibility of locus coeruleus and substantia nigra imaging
401 with neuromelanin sensitive MRI. *MAGMA*. 2017;30(2):121-5. doi: 10.1007/s10334-016-0590-z. PubMed PMID:
402 27687624.
- 403 19. Wengler K, He X, Abi-Dargham A, Horga G. Reproducibility assessment of neuromelanin-sensitive
404 magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. *Neuroimage*. 2020;208:116457.
405 Epub 2019/12/17. doi: 10.1016/j.neuroimage.2019.116457. PubMed PMID: 31841683; PubMed Central PMCID:
406 PMC67118586.
- 407 20. van der Pluijm M, Cassidy C, Zandstra M, Wallert E, de Bruin K, Booij J, et al. Reliability and
408 Reproducibility of Neuromelanin-Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different
409 Sequences. *J Magn Reson Imaging*. 2021;53(3):712-21. Epub 2020/10/11. doi: 10.1002/jmri.27384. PubMed PMID:
410 33037730; PubMed Central PMCID: PMC67891576.
- 411 21. Ohtsuka C, Sasaki M, Konno K, Koide M, Kato K, Takahashi J, et al. Changes in substantia nigra and
412 locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. *Neurosci*
413 *Lett* 2013;541:93-8.

- 414 22. Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, et al. Neuromelanin magnetic
415 resonance imaging in Parkinson's disease and multiple system atrophy. *Eur Neurol.* 2013;70(1-2):70-7. Epub
416 2013/06/26. doi: 000350291 [pii]10.1159/000350291. PubMed PMID: 23796701.
- 417 23. Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O, Ortega-Cubero S, Puigvert M, Uranga J, et al.
418 Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease. *Mov Disord.*
419 2015;30(7):945-52. doi: 10.1002/mds.26201. PubMed PMID: 25772492.
- 420 24. Langley J, Hwang KS, Hu XP, Huddleston DE. Nigral volumetric and microstructural measures in
421 individuals with scans without evidence of dopaminergic deficit. *Front Neurosci.* 2022;16:1048945. Epub 20221124.
422 doi: 10.3389/fnins.2022.1048945. PubMed PMID: 36507343; PubMed Central PMCID: PMCPCMC9731284.
- 423 25. Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-weighted MRI shows stage-
424 dependent substantia nigra signal loss in Parkinson's disease. *Mov Disord.* 2011;26(9):1633-8. Epub 2011/04/15. doi:
425 10.1002/mds.23722. PubMed PMID: 21491489.
- 426 26. Reimao S, Pita Lobo P, Neutel D, Correia Guedes L, Coelho M, Rosa MM, et al. Substantia nigra
427 neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. *Eur J Neurol.* 2015;22(3):540-6.
428 doi: 10.1111/ene.12613. PubMed PMID: 25534480.
- 429 27. Huddleston DE, Langley J, Sedlacik J, Boelmans K, Factor SA, Hu XP. In vivo detection of lateral-ventral
430 tier nigral degeneration in Parkinson's disease. *Hum Brain Mapp.* 2017;38(5):2627-34. doi: 10.1002/hbm.23547.
431 PubMed PMID: 28240402; PubMed Central PMCID: PMCPCMC5385149.
- 432 28. Pyatigorskaya N, Magnin B, Mongin M, Yahia-Cherif L, Valabregue R, Arnaldi D, et al. Comparative
433 Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease. *AJNR Am J*
434 *Neuroradiol.* 2018;39(8):1460-7. Epub 2018/06/30. doi: 10.3174/ajnr.A5702. PubMed PMID: 29954816; PubMed
435 Central PMCID: PMCPCMC7410545.
- 436 29. Langley J, Huddleston DE, Merritt M, Chen X, McMurray R, Silver M, et al. Diffusion tensor imaging of
437 the substantia nigra in Parkinson's disease revisited. *Hum Brain Mapp.* 2016;37(7):2547-56. doi:
438 10.1002/hbm.23192. PubMed PMID: 27029026.
- 439 30. Langley J, Huddleston DE, Hu X. Nigral diffusivity, but not free water, correlates with iron content in
440 Parkinson's disease. *Brain Commun.* 2021;3(4):fcab251. Epub 2021/11/23. doi: 10.1093/braincomms/fcab251.
441 PubMed PMID: 34805996; PubMed Central PMCID: PMCPCMC8599079.
- 442 31. Isaias IU, Trujillo P, Summers P, Marotta G, Mainardi L, Pezzoli G, et al. Neuromelanin Imaging and
443 Dopaminergic Loss in Parkinson's Disease. *Front Aging Neurosci.* 2016;8:196. doi: 10.3389/fnagi.2016.00196.
444 PubMed PMID: 27597825; PubMed Central PMCID: PMCPCMC4992725.
- 445 32. Langley J, He N, Huddleston DE, Chen S, Yan F, Crosson B, et al. Reproducible detection of nigral iron
446 deposition in 2 Parkinson's disease cohorts. *Mov Disord.* 2019;34(3):416-9. doi: 10.1002/mds.27608. PubMed
447 PMID: 30597635.
- 448 33. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related
449 to sporadic Parkinson's disease. *Neurobiology of Aging.* 2003;24(2):197-211.
- 450 34. Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP. In Vivo Assessment of Brainstem Depigmentation in
451 Parkinson Disease: Potential as a Severity Marker for Multicenter Studies. *Radiology.* 2016:160662. doi:
452 10.1148/radiol.2016160662. PubMed PMID: 27820685.
- 453 35. Sasaki M, Shibata E, Tohyama K, Kudo K, Endoh J, Otsuka K, et al. Monoamine neurons in the human
454 brain stem: anatomy, magnetic resonance imaging findings, and clinical implications. *Neuroreport.*
455 2008;19(17):1649-54. Epub 2008/10/15. doi: 10.1097/WNR.0b013e328315a637. PubMed PMID: 18852680.
- 456 36. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for
457 Parkinson's disease. *Mov Disord.* 2015;30(12):1591-601. doi: 10.1002/mds.26424. PubMed PMID: 26474316.
- 458 37. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES/ENS
459 [corrected] recommendations for the diagnosis of Parkinson's disease. *Eur J Neurol.* 2013;20(1):16-34. doi:
460 10.1111/ene.12022. PubMed PMID: 23279440.

- 461 38. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal
462 Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.*
463 2005;53(4):695-9. Epub 2005/04/09. doi: 10.1111/j.1532-5415.2005.53221.x. PubMed PMID: 15817019.
- 464 39. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International
465 multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's
466 disease: the NMSQuest study. *Mov Disord.* 2006;21(7):916-23. Epub 2006/03/21. doi: 10.1002/mds.20844. PubMed
467 PMID: 16547944.
- 468 40. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep
469 behavior disorder screening questionnaire--a new diagnostic instrument. *Mov Disord.* 2007;22(16):2386-93. Epub
470 2007/09/27. doi: 10.1002/mds.21740. PubMed PMID: 17894337.
- 471 41. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances in
472 functional and structural MR image analysis and implementation as FSL. *NeuroImage.* 2004;23 Suppl 1:S208-19.
473 Epub 2004/10/27. doi: S1053-8119(04)00393-3 [pii]10.1016/j.neuroimage.2004.07.051. PubMed PMID: 15501092.
- 474 42. Woolrich MW, Jbabdi S, Patenaude B, Chappell M, Makni S, Behrens T, et al. Bayesian analysis of
475 neuroimaging data in FSL. *NeuroImage.* 2009;45(1 Suppl):S173-86. Epub 2008/12/09. doi: S1053-8119(08)01204-4
476 [pii]10.1016/j.neuroimage.2008.10.055. PubMed PMID: 19059349.
- 477 43. Langley J, Hussain S, Flores JJ, Bennett IJ, Hu X. Characterization of age-related microstructural changes
478 in locus coeruleus and substantia nigra pars compacta. *Neurobiol Aging.* 2020;87:89-97. doi:
479 10.1016/j.neurobiolaging.2019.11.016. PubMed PMID: 31870645.
- 480 44. Ma SY, Roytt M, Collan Y, Rinne JO. Unbiased morphometrical measurements show loss of pigmented
481 nigral neurones with ageing. *Neuropathol Appl Neurobiol.* 1999;25(5):394-9. PubMed PMID: 10564529.
- 482 45. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, et al. The role of iron and copper
483 molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. *Proc Natl Acad Sci U S*
484 *A.* 2004;101(26):9843-8. doi: 10.1073/pnas.0403495101.
- 485 46. Manaye KF, McIntire DD, Mann DM, German DC. Locus coeruleus cell loss in the aging human brain: a
486 non-random process. *J Comp Neurol.* 1995;358(1):79-87. doi: 10.1002/cne.903580105. PubMed PMID: 7560278.
- 487 47. Cheng Z, He N, Huang P, Li Y, Tang R, Sethi SK, et al. Imaging the Nigrosome 1 in the substantia nigra
488 using susceptibility weighted imaging and quantitative susceptibility mapping: An application to Parkinson's disease.
489 *Neuroimage Clin.* 2020;25:102103. doi: 10.1016/j.nicl.2019.102103. PubMed PMID: 31869769; PubMed Central
490 PMCID: PMC6933220.
- 491 48. Li G, Zhai G, Zhao X, An H, Spincemaille P, Gillen KM, et al. 3D texture analyses within the substantia
492 nigra of Parkinson's disease patients on quantitative susceptibility maps and R2(*) maps. *Neuroimage.*
493 2019;188:465-72. doi: 10.1016/j.neuroimage.2018.12.041. PubMed PMID: 30578927.
- 494 49. Ariz M, Abad RC, Castellanos G, Martinez M, Munoz-Barrutia A, Fernandez-Seara MA, et al. Dynamic
495 Atlas-Based Segmentation and Quantification of Neuromelanin-Rich Brainstem Structures in Parkinson Disease.
496 *IEEE Trans Med Imaging.* 2019;38(3):813-23. doi: 10.1109/TMI.2018.2872852. PubMed PMID: 30281440.
- 497 50. Shinde S, Prasad S, Saboo Y, Kaushick R, Saini J, Pal PK, et al. Predictive markers for Parkinson's disease
498 using deep neural nets on neuromelanin sensitive MRI. *Neuroimage Clin.* 2019;22:101748. doi:
499 10.1016/j.nicl.2019.101748. PubMed PMID: 30870733; PubMed Central PMCID: PMC6417260.
- 500 51. Biondetti E, Santin MD, Valabregue R, Mangone G, Gaurav R, Pyatigorskaya N, et al. The spatiotemporal
501 changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. *Brain.* 2021;144(10):3114-25. doi:
502 10.1093/brain/awab191. PubMed PMID: 33978742; PubMed Central PMCID: PMC68634084.
- 503 52. Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, et al. Diffusion imaging of nigral
504 alterations in early Parkinson's disease with dopaminergic deficits. *Mov Disord.* 2015;30(14):1885-92. Epub
505 2015/08/12. doi: 10.1002/mds.26325. PubMed PMID: 26260437.
- 506 53. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of
507 dopamine-containing neurons in Parkinson's disease. *Brain.* 1999;122 (Pt 8):1437-48. Epub 1999/08/04. PubMed
508 PMID: 10430830.


- 509 54. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and
510 the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. *Brain*. 1999;122
511 (Pt 8):1421-36. Epub 1999/08/04. PubMed PMID: 10430829.
- 512 55. Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, et al. Visualization of nigrosome
513 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. *Neurology*. 2013;81(6):534-40. Epub
514 2013/07/12. doi: WNL.0b013e31829e6fd2 [pii]10.1212/WNL.0b013e31829e6fd2. PubMed PMID: 23843466;
515 PubMed Central PMCID: PMC3775686.
- 516 56. Langley J, Huddleston DE, Crosson B, Song DD, Factor SA, Hu X. Multimodal assessment of nigrosomal
517 degeneration in Parkinson's disease. *Parkinsonism & related disorders*. 2020;80:102-7. Epub 2020/09/27. doi:
518 10.1016/j.parkreldis.2020.09.021. PubMed PMID: 32979784; PubMed Central PMCID: PMC7738361.
- 519 57. Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-Weighted MRI shows stage-
520 dependent substantia nigra signal loss in Parkinson's disease. *Mov Disord*. 2011;26(9):1633-38.
- 521 58. Planetta PJ, Ofori E, Pasternak O, Burciu RG, Shukla P, DeSimone JC, et al. Free-water imaging in
522 Parkinson's disease and atypical parkinsonism. *Brain*. 2016;139(Pt 2):495-508. doi: 10.1093/brain/awv361. PubMed
523 PMID: 26705348.
- 524 59. Zhou L, Li G, Zhang Y, Zhang M, Chen Z, Zhang L, et al. Increased free water in the substantia nigra in
525 idiopathic REM sleep behaviour disorder. *Brain*. 2021;144(5):1488-97. Epub 2021/04/22. doi:
526 10.1093/brain/awab039. PubMed PMID: 33880500.
- 527 60. Febo M, Perez PD, Ceballos-Diaz C, Colon-Perez LM, Zeng H, Ofori E, et al. Diffusion magnetic
528 resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-gamma. *Brain Struct*
529 *Funct*. 2020;225(1):427-39. Epub 2020/01/03. doi: 10.1007/s00429-019-02017-1. PubMed PMID: 31894407;
530 PubMed Central PMCID: PMC7003714.
- 531 61. Langley J, Huddleston DE, Sedlacik J, Boelmans K, Hu XP. Parkinson's disease-related increase of T2*-
532 weighted hypointensity in substantia nigra pars compacta. *Mov Disord*. 2017;32(3):441-9. doi: 10.1002/mds.26883.
533 PubMed PMID: 28004859.
- 534 62. He N, Langley J, Huddleston DE, Chen S, Huang P, Ling H, et al. Increased iron-deposition in lateral-
535 ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease. *Neuroimage Clin*.
536 2020;28:102391. Epub 2020/09/06. doi: 10.1016/j.nicl.2020.102391. PubMed PMID: 32889398; PubMed Central
537 PMCID: PMC7479276.
- 538
- 539

540 **Figures**



541
542 **Fig 1.** A pictorial representation of the segmentation procedure for SNc and LC. The first
543 column shows the reference ROI in blue and the SNc atlas (top) or LC atlas (bottom) in red-
544 yellow in MNI space. These ROIs were transformed to native space, and the atlases were
545 threshold at a level of 5% and dilated (shown in red in the middle column). Voxels in the dilated
546 region above the threshold were considered to be part of the SNc and LC (third column),
547 respectively.

548




549

550

551 **Fig 2.** A comparison of mean LC contrast in control (top row) and PD (bottom row) groups for
552 both cohorts. Mean MTC images from cohort 1 are shown in the left column while mean MTC
553 images from cohort 2 are shown in the right column. For each group, the mean MTC image was
554 created by transforming MTC images from individual participants to MNI space and then
555 averaging. In each image, yellow arrows indicate the location of LC.

556




557

558

559 **Fig 3.** A comparison of mean SNc contrast in control (top row) and PD (bottom row) groups for
560 both cohorts. Mean MTC images from cohort 1 are shown in the left column while mean MTC
561 images from cohort 2 are shown in the right column. For each group, the mean MTC image was
562 created by transforming MTC images from individual participants to MNI space and then
563 averaging. Regions experiencing PD-related neuronal loss are indicated by yellow arrows in the
564 bottom row.

565




566

567

568 **Fig 4.** Group comparisons for LC volume (A) and SNc volume (B) in both cohorts. Similar
569 reductions in LC and SNc volume are observed in both cohorts. In (A) and (B), the box denotes
570 the 25th and 75th percentile, respectively, with the line denoting the median value.

571



572

573

574 **Fig 5.** ROC analysis assessing performance of SNc and LC volumes to differentiate PD from
575 controls. ROC curves for Cohort 1 and Cohort 2 are shown in (A) and (B), respectively.